Beau M. Ances, MD, PhD
The Ances lab is a neuroscience research lab that is focused on:
- Developing novel neuroimaging biomarkers of normal aging and neurodegeneration (including Alzheimer’s Disease (AD), Down syndrome (DS), HIV Associated Neurocognitive Disorders (HAND), Creutzfeld-Jacob Disease (CJD), autoimmune- mediated encephalitis (AIME), and neuroCOVID19).
- Evaluating therapeutic interventions that will improve neurocognitive deficits and biomarkers associated with neurodegenerative disorders.
Joyce Balls-Berry, PhD
Joyce (Joy) E. Balls-Berry, PhD, is a psychiatric epidemiologist and health educator. Her primary research focuses on applying community and patient-engaged research principles in diverse populations to reduce health disparities and increase health equity. Much of Balls-Berry’s research centers on determining ways to increase diversity and inclusion in clinical and translational science.
Randall Bateman, MD
Our laboratory’s focus is the causes, diagnosis and future treatments of Alzheimer disease. We directly measure the pathophysiology of Alzheimer disease in humans using multiple techniques and also perform in vitro cell culture experiments.
Michael Belloy, PhD
Our research is dedicated to understanding the genetics of Alzheimer’s disease and related disorders. We utilize functional genomics and bioinformatics tools to analyze publicly available cohort and population data. Our primary goal is to identify novel genetic risk variants for Alzheimer’s disease and elucidate their molecular mechanisms. This knowledge will inform drug development and advance the field of personalized genetic medicine.
Matthew R. Brier, MD, PhD
The Brier lab uses neuroimaging to study multiple sclerosis (MS). Advances in disease modifying therapies allow for the reduction of inflammatory relapses in patients with MS. However, despite these incredible treatments, many patients still experience progressive disability accumulation associated with neurodegeneration. We are principally interested in how this progressive degenerative pathology emerges in the context of seemingly well treated relapsing MS.
John Cirrito, PhD
The Cirrito lab focuses on understanding the metabolism Abeta within the brain extracellular fluid or interstitial fluid (ISF). It developed a novel in vivo microdialysis technique that enables us to specifically measure ISF Abeta within the brains of living and awake wildtype and APP transgenic mice.
David Clifford, MD
David Clifford, MD, has a broad interest in neuropharmacology. His clinical focus is the development of more successful medical management of neurological disease. He's participated in studies of epilepsy, Parkinson’s disease, multiple sclerosis and virtually all neurologic complications of HIV.
Anne Cross, MD
The goal of the Cross lab's research is to understand the mechanisms involved in pathogenesis of inflammation and demyelination in the central nervous system (brain and spinal cord).
Albert (Gus) Davis, MD
The primary goal of our research is to increase our understanding of the basic pathophysiological mechanisms underlying protein aggregation and neurodegeneration in synucleinopathies in order to pave the way for improved diagnostic tests and disease-modifying treatments for these illnesses.
Rajat Dhar, MD, FRCPC
The Dhar lab seeks to leverage data and image-driven approaches to understand the heterogeneity of human responses to severe brain injuries.